fbpx

NCI’s Global Cancer Medicine Humanitarian Award awarded to Pat Garcia-Gonzalez

Boston, Massachusetts; USA

The Max Foundation is proud to announce CEO, Pat Garcia-Gonzalez as the recipient of the National Cancer Institute Global Cancer Medicine Humanitarian Award at the U.S. National Cancer Institute 3rd Annual Symposium on Global Cancer Research held in Boston on 25 March 2015.

In the award letter from the National Cancer Institute (NCI), Dr. Edward L. Trimble, MD, MPH, Director of the NCI’s Center for Global Health writes about Pat: “Our global cancer community has been inspired by your outstanding contributions to advancing cancer care equity through The Max Foundation, and as recognition of that work, we would like to honor you.”

Dr. Trimble continues, “Not only have your efforts saved numerous lives, but, to paraphrase Donald Berwick, your contributions go beyond health metrics and health indicators— your contributions will allow mothers and fathers to attend graduations and weddings they would have missed, and grandchildren to know grandparents they might never have known, “and holidays will be taken, and work completed, and books read, and symphonies heard, and gardens tended that, without your work, would never have been.’”

In response to the award, Pat has said, “I am humbled, excited and honored by the recognition given to me thanks to NCI’s Center for Global Health. I see this moment as an opportunity to tell the world about the great collaborations that have made my work possible, as well as a chance to reinforce our collective responsibility around creating solutions to increase global access to treatment, care and support for people living with cancer around the world.”

This is the first Global Cancer Medicine Humanitarian Award to be given at the NCI’s Symposium.

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 27 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • Celebrating One Year of Spot On CML

    Celebrating One Year of Spot On CML

    The numbers are in! The Max Foundation is thrilled to announce that Spot On CML, our diagnostic collaboration with Fred Hutchinson Cancer Research Center, has provided free testing to 371 patients across 15 countries in its inaugural year.

  • Innovator Jerry Radich of Fred Hutch joins The Max Foundation’s Executive Board

    Innovator Jerry Radich of Fred Hutch joins The Max Foundation’s Executive Board

    The Max Foundation is thrilled to welcome longtime advisor, Dr. Jerald Radich of the Fred Hutchinson Cancer Research Institute into the Executive Board.  Dr. Radich has been a guiding star in our innovative work for many years helping people face cancer with dignity and hope, especially in the area of improving access to critical diagnostics in low- and middle-income countries.

  • New study confirms an excellent survival rate of cancer patients in a medication donation program

    New study confirms an excellent survival rate of cancer patients in a medication donation program

    A new study led by Boston University School of Public Health, The Max Foundation, and Novartis Oncology found that chronic myeloid leukemia (CML) patients taking first-line treatment in low- and middle-income countries (LMICs) as part of the Glivec International Patient Assistance Program (GIPAP) have survival rates that compare favorably to those of CML patients receiving treatment in high-income countries.